Identifies inhibitors of Vibrio beta-lactam resistance in zebrafish, suggesting new treatment strategies.
transcription without affecting bacterial growth but markedly potentiated the activity of β-lactam antibiotics. In a bacteria-challenged zebrafish model, LPZ-51 synergized with carbenicillin to reduce bacterial burden, alleviate intestinal inflammation, and improve host survival. Together, these findings demonstrate that targeting VbrK attenuates β-lactam resistance by blocking β-lactamase induction at the transcriptional level, providing a mechanistically distinct antiresistance strategy complementary to existing β-lactam therapies.
No takes yet. Share an insight, caveat, or question.
靳博 et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: